ECSP10010719A - Una nueva sal de glicinato de metformina para el control de la glucosa en sangre - Google Patents

Una nueva sal de glicinato de metformina para el control de la glucosa en sangre

Info

Publication number
ECSP10010719A
ECSP10010719A EC2010010719A ECSP10010719A ECSP10010719A EC SP10010719 A ECSP10010719 A EC SP10010719A EC 2010010719 A EC2010010719 A EC 2010010719A EC SP10010719 A ECSP10010719 A EC SP10010719A EC SP10010719 A ECSP10010719 A EC SP10010719A
Authority
EC
Ecuador
Prior art keywords
salt
metformin
glycinate
hydrochloride
exhibits
Prior art date
Application number
EC2010010719A
Other languages
English (en)
Inventor
Ochoa Jose Manuel Francisco Lara
Original Assignee
Silanes Sa De Cv Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40383805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010719(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Silanes Sa De Cv Lab filed Critical Silanes Sa De Cv Lab
Publication of ECSP10010719A publication Critical patent/ECSP10010719A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a la síntesis de una nueva sal de Glicinato 1,1-dimetilbiguanid, llamada Glicinato de Metformina diseñada para el control de la glucosa en sangre. Esta sal exhibe ventajas sobre otras sales de metformina. Estas ventajas se refieren, en primer lugar, al hecho de que el contraión exhibe efectos hipoglucemientes por sí mismos, el efecto hipoglucemiente es más pronunciado. Además esta sal exhibe una mejor absorción, alcanzando una concentración plasmática más alta que aquella producida con clorhidrato de metfromina. La síntesis se llevó a cabo a partir de clorhidrato de metformina liberando el contraión hidrocloruro, usando una columna de intercambio iónico, la metformina liberada se disolvió en medio acuoso y subsecuentemente se adicionó glicina a temperatura ambiente y agitación constante, el producto resultante se calienta produciendo una solución concentrada del producto, se adiciona un solvente orgánico para crear insolubilidad y favorecer la cristalización en un medio saturado, el exceso de glicina precipita y se obtiene la sal glicinato de metfromina después de filtrar y concentrar dicha sal. La sal Glicinato de Metformina presenta un efecto farmacológico más pronunciado en la reducción de los niveles de glucosa en sangre.
EC2010010719A 2008-06-26 2010-12-24 Una nueva sal de glicinato de metformina para el control de la glucosa en sangre ECSP10010719A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/002665 WO2009144527A1 (en) 2008-06-26 2008-06-26 A new metformin glycinate salt for blood glucose control

Publications (1)

Publication Number Publication Date
ECSP10010719A true ECSP10010719A (es) 2011-01-31

Family

ID=40383805

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010719A ECSP10010719A (es) 2008-06-26 2010-12-24 Una nueva sal de glicinato de metformina para el control de la glucosa en sangre

Country Status (26)

Country Link
US (2) US8703183B2 (es)
EP (1) EP2303838B1 (es)
JP (1) JP5551691B2 (es)
KR (1) KR101522066B1 (es)
CN (1) CN102159539B (es)
AR (1) AR074159A1 (es)
AU (1) AU2008357111B2 (es)
BR (1) BRPI0822909B8 (es)
CA (1) CA2729035C (es)
CL (1) CL2009001484A1 (es)
CY (1) CY1115098T1 (es)
DK (1) DK2303838T3 (es)
EC (1) ECSP10010719A (es)
ES (1) ES2450148T3 (es)
HR (1) HRP20140194T1 (es)
JO (1) JO2884B1 (es)
MA (1) MA32418B1 (es)
MX (1) MX2011000135A (es)
NI (1) NI201000234A (es)
PE (1) PE20100257A1 (es)
PL (1) PL2303838T3 (es)
PT (1) PT2303838E (es)
SI (1) SI2303838T1 (es)
TN (2) TN2010000607A1 (es)
UY (1) UY31945A (es)
WO (1) WO2009144527A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011000135A (es) 2008-06-26 2011-02-25 Silanes Sa De Cv Lab Una nueva sal de glicinato de metformina para el control de la glucosa en sangre.
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
CN103263405B (zh) * 2013-05-08 2015-04-22 南京医科大学 用于治疗糖尿病的药物组合物及其应用
WO2015042495A2 (en) * 2013-09-22 2015-03-26 Jiva Pharma, Inc. Metformin salts to treat type2 diabetes
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
EP3140316A1 (en) 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
CN107074884A (zh) 2014-06-18 2017-08-18 西蒂斯制药有限责任公司 活性剂的矿物质氨基酸复合物
AU2015339576B2 (en) 2014-10-27 2020-02-06 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
CN105030745A (zh) * 2015-07-08 2015-11-11 南京医科大学 甘氨酸和二甲双胍的酰胺化产物在制备治疗糖尿病药物中的应用
EP3337402A4 (en) 2015-08-20 2019-04-24 Aseko, Inc. THERAPY ADVISER FOR THE MANAGEMENT OF DIABETES
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
WO2018060962A2 (en) 2016-09-30 2018-04-05 Laboratorios Silanes S.A. De C.V. Metformin amino acid compounds and methods of using the same
WO2018060959A1 (en) * 2016-09-30 2018-04-05 Laboratorios Silanes S.A. De C.V. Metformin glycinate, pharmaceutical compositions comprising the same, and methods of using the same
CN113105367B (zh) * 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用
CN114349665B (zh) * 2021-11-30 2023-06-09 潍坊博创国际生物医药研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE568513A (es)
FR2037002A1 (en) 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
DE1967138A1 (de) 1969-07-17 1977-11-10 Christian Brunnengraeber Chem Therapeutisches mittel
AT325632B (de) 1973-06-01 1975-10-27 Hurka Wilhelm Verfahren zur herstellung von nicotinsauren salzen von derivaten des biguanids
FR2243684B1 (es) 1973-09-19 1977-01-28 Semb
CH602612A5 (es) 1974-10-11 1978-07-31 Hoffmann La Roche
FR2320735A1 (fr) 1975-08-12 1977-03-11 Dabis Georges Composition anti-cellulite
JPS57179494A (en) 1981-04-30 1982-11-05 Mitsubishi Plastics Ind Method of closing through hole of pipe, circumferential wall thereof has through hole in pipe axial direction
FR2585572B3 (fr) 1985-07-31 1987-12-31 Hugelin Andre Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse
PT793646E (pt) * 1994-11-23 2002-03-28 Biovitrum Ab Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente
AU738804B2 (en) 1997-12-08 2001-09-27 Bristol-Myers Squibb Company Novel salts of metformin and method
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
US20030220301A1 (en) * 2002-02-14 2003-11-27 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US7181457B2 (en) * 2003-05-28 2007-02-20 Pervasive Software, Inc. System and method for utilizing compression in database caches to facilitate access to database information
US20050163850A1 (en) 2003-10-31 2005-07-28 Wong Patrick S. Administration of levodopa and carbidopa
WO2005065675A1 (en) 2004-01-07 2005-07-21 Premacs International Pty. Ltd. Method of treatment
EP2242489A1 (en) * 2005-02-15 2010-10-27 Jallal Messadek Combination therapeutic compositions and method of use
MX2007013486A (es) * 2005-04-27 2008-03-14 Jallal Messadek Combinaciones de insulinas.
JP2009541220A (ja) * 2006-06-16 2009-11-26 インディジーン ファーマシューティカルズ インコーポレイテッド 糖尿病性高血糖および糖尿病合併症の制御のための抗糖尿病薬としてのメトホルミンｒ−（＋）リポエート
NZ556735A (en) * 2007-07-24 2009-03-31 Vector Ltd Securing devices and equipotential bonding system
MX2011000135A (es) 2008-06-26 2011-02-25 Silanes Sa De Cv Lab Una nueva sal de glicinato de metformina para el control de la glucosa en sangre.

Also Published As

Publication number Publication date
CN102159539B (zh) 2014-04-16
ES2450148T3 (es) 2014-03-24
BRPI0822909B1 (pt) 2019-11-12
AU2008357111B2 (en) 2013-05-09
CL2009001484A1 (es) 2009-12-04
HRP20140194T1 (hr) 2014-06-20
PL2303838T3 (pl) 2014-07-31
SI2303838T1 (sl) 2014-07-31
US8703183B2 (en) 2014-04-22
JP5551691B2 (ja) 2014-07-16
MA32418B1 (fr) 2011-06-01
DK2303838T3 (en) 2014-03-03
WO2009144527A1 (en) 2009-12-03
AR074159A1 (es) 2010-12-29
UY31945A (es) 2010-01-05
MX2011000135A (es) 2011-02-25
CA2729035A1 (en) 2009-12-03
PT2303838E (pt) 2014-03-10
EP2303838A1 (en) 2011-04-06
USRE46496E1 (en) 2017-08-01
BRPI0822909A2 (pt) 2015-06-30
NI201000234A (es) 2012-03-19
PE20100257A1 (es) 2010-04-10
TN2010000604A1 (en) 2012-05-24
CN102159539A (zh) 2011-08-17
KR20110042165A (ko) 2011-04-25
KR101522066B1 (ko) 2015-05-20
JP2011525900A (ja) 2011-09-29
EP2303838B1 (en) 2013-12-04
BRPI0822909B8 (pt) 2021-05-25
US20110171142A1 (en) 2011-07-14
TN2010000607A1 (en) 2012-05-24
CA2729035C (en) 2015-10-20
CY1115098T1 (el) 2016-12-14
JO2884B1 (en) 2015-03-15
AU2008357111A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
ECSP10010719A (es) Una nueva sal de glicinato de metformina para el control de la glucosa en sangre
ES2626645T3 (es) Proceso para la preparación de aminopirrolidinas quirales ópticamente activas (3-AP, B3-AP)
ES2656239T3 (es) Método de preparación de la forma cristalina I del racemato de 4-hidroxido-2-oxo-1-pirrolidina-acetamida
AR062134A1 (es) Erlotinib cristalino
AR067775A1 (es) (2s,3r)-n-(2-((3- piridinil) metil)-1- azabiciclo (2.2.2= oct-3-il) benzofuran -2- carboxamida, formas de sales y metodos de uso
AR057554A1 (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas
PE20081390A1 (es) Procedimiento para producir derivados de amina opticamente activos
AR063923A1 (es) Sales del acido zoledronico, procesos de preparacion y composiciones
AR074894A1 (es) Procedimiento para purificar un alcohol a partir de un caldo de fermentacion usando un evaporador de pelicula descendente , de pelicula agitada o de corto recorrido
BR112015000088A2 (pt) composições farmacêuticas compreendendo rifamixinaa e aminoácidos, método de preparação e uso das mesmas
AR075097A1 (es) Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia
CL2008001131A1 (es) Solucion de manoproteinas; proceso para producir dicha solucion de manoproteinas; proceso para estabilizar vino impidiendo o retardando la cristalizacion de sales de acido tartarico.
DOP2010000403A (es) Una nueva sal de glicinato de metformina para el control de la glucosa en sangre
CO6331332A2 (es) Una nueva sal de glicinato de metformina para el control de glucosa en sangre
AR081890A1 (es) Procesos para la preparacion de cloruro de glicopirronio, composiciones farmaceuticas que lo contienen y su uso para tratar enfermedades respiratorias
HN2010002738A (es) Una nueva sal de glicinato de metformina para el control de la glucosa en sangre
SV2010003780A (es) Una nueva sal de glicinato de metformina para el control de la glucosa en sangre
ATE438612T1 (de) Neuartiges verfahren zur herstellung von quaternärer säure und ammoniumsalzen
DE602007013796D1 (de) Ausstossflüssigkeit und ausstossverfahren
FR2912406B1 (fr) Sels cristalins anhydres de vinflunine, procede de preparation et utilisation en tant que medicament et moyen de purification de la vinflunine.
BR0314526A (pt) Composições farmacêuticas para o tratamento do mal de parkinson
BRPI0519064A2 (pt) uso de derivados de Ácido ciclo propano substituÍdos para produÇço de fÁrmacos para uso no tratamento de sÍndrome metabàlica
ES2657894T3 (es) Preparación de un derivado de ácido 1-amino-3-hidroxi-ciclobutano-1-carboxílico
PE20091311A1 (es) Nuevo proceso para preparar la forma a del acido (2r)-(3-amino-2-fluoropropil)fosfinico
TH66581A (th) วิธีการทำให้สาร 1, 1-บิส(4'-ไฮดรอกซี-3'-เมธิลเฟนิล) ไซโคลเฮกเซนบริสุทธิ์ และวิธีการผลิตสารโพลีคาร์บอร์เนตจากการสารดังกล่าว